To accelerate the availability of rejuvenation therapies, we make lighthouse investments in entirely new, repair-based approaches that treat the root causes of aging and thus overcome age-related diseases.
Through the creation of successful companies, we seek to inspire scientists, investors, and the general public by demonstrating that human rejuvenation is not science fiction anymore and that the resulting therapies are affordable and uncomplicated.
Technologies pioneered by our startups include removal of arterial plaque, decalcification of aged tissue, breaking of protein-glucose cross-links, and delivery of new mitochondria to aged cells – all aiming to prevent and repair common age-related conditions such as myocardial infarction, stroke, high blood pressure, tissue stiffening, skin aging, and loss of muscle function.
Mentoring and support for these teams are handled by Michael’s VC company Kizoo.
MoglingBio Inc. is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. Aging causes stem cells to lose their normal structure by increased activity of the protein CDC42. This loss of structure leads to decreased production and quality of blood and immune cells. It can cause leukemia, various blood diseases, and severely weaken the immune system. Normalizing CDC42 activity can restore structure, order and functionality in those aged stem cells. Treated cells can perform their tasks again in a juvenile way, and thereby contribute to both, the rejuvenation of stem cells and the immune system.
Elastrin is developing therapeutics that render calcified tissue and organs supple again by removing pathological calcification, specifically from sites where elastin has been degraded.
Its underlying technology was developed by Dr. Naren Vyavahare and Dr. Charles Rice over the last 20 years at Clemson University. The Elastrin team has developed a platform that allows for substantial rejuvenation of the cardiovascular system and could restore organ function & skin elasticity to youthful levels. This is achieved by targeting albumin nanoparticles loaded with therapeutic agents directly to the tissue site of interest with the company’s proprietary anti-elastin monoclonal antibody.
Cellvie is a Harvard spin-off pioneering Therapeutic Mitochondria Transfer (TMT) leveraging the therapeutic potential of mitochondria.
The company was founded by Drs. McCully, Schueller, del Nido and Emani. Dr. McCully pioneered the approach of mitochondria augmentation and replacement at Harvard Medical School and the team has now set out to bring it about as a new treatment modality in ischemia-reperfusion injury and beyond to slow or reverse degenerative processes of aging linked to the mitochondria.
Revel opens up an entirely new field in the treatment of age-related molecular damage – breaking crosslinked collagen fibers.
Collagen is an essential part of the structural framework of the body. Unfortunately, it sometimes binds with glucose to form stiff, sofar unbreakable bonds that accumulate over time. Crosslinks cause hardening of tissues such as muscle, skin, and arteries leading to increased blood pressure, vascular damage, and wrinkling of the skin.
Revel will produce crosslink-breaking drugs.
The basic technology was developed at Yale University, funded by the SENS Research Foundation and the Forever Healthy Foundation.
Cyclarity develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause – a build-up of arterial plaque.
The company’s technology removes arterial plaque by clearing the non-degradable cholesterol that accumulates within cells in the arterial walls.
Cyclarity’s long-term goal is to deliver a simple and affordable preventive therapy for the world.
The basic technology was developed in the SENS lab, co-funded by the Forever Healthy Foundation.
LIfT Biosciences is developing the world’s first cell therapy to destroy all solid tumours, irrespective of strain or mutation by building the World’s 1st cell bank of innately cancer killing neutrophils (a type of white blood cell).
The cell bank will enable LIfT to provide a range of potentially life-saving immuno-oncology cell therapies for different solid tumour types. The first step is to show remission in high unmet need solid tumours by 2021, including Pancreatic Cancer.
MAIA Biotechnology is dedicated to developing targeted cancer therapies with novel mechanisms of action that are intended to meaningfully improve and extend the lives of patients with cancer.
Telomerase is present in 90% of human cancer cells and contributes significantly to proliferative abilities and immortality of cancer cells. It is either absent or shows low activity in normal cells.
THIO(6-thio-dG) is recognized by telomerase and incorporated into telomeres. Once incorporated, it compromises telomere structure and function, leading to ‘uncapping’ of the chromosome ends resulting in rapid tumor cell death.
Turn Biotechnologies is developing therapies to effectively return mature differentiated cells to a dramatically younger state leaving their differentiated identity unaltered.
Turn Biotechnologies surpasses traditional approaches based on single gene/pathway manipulations and tackles the multifaceted manifestation of cellular age at the organ, tissue, and organismal level to extend the healthspan of people. As a result, age is reset by epigenetically reprogramming cells.
Elevian is a Harvard spinout developing therapeutics to stimulate regenerative capacity, the body’s ability to repair itself, that declines as we age.
Elevian’s founders have identified circulating blood factors, including GDF11, that broadly stimulate regenerative capacity in aged animals in many organs and tissues (e.g. brain, heart, pancreas, muscle, and others). Initially planned indications include Alzheimer’s disease, heart failure, Type II diabetes, and age-related muscle dysfunction.
Antoxerene uses proprietary next generation screening technology to identify small-molecule compounds that target pathways of aging.
The team focuses on next generation screens with higher predictive value than traditional approaches and expects first on-target therapeutic candidates for the p53/MDM2 pathway, a major oncology target, and the p53/FOXO4 pathway, a newly identified pathway involved in cellular aging.
FoxBio will develop Antoxerene’s collection of small molecules that specifically target senescent cells.
There has been a lot of interest surrounding the therapeutic applications of senolytic drugs – compounds that clear toxic senescent cells – particularly with respect to age-associated disease. As molecular pathways unique to senescent cells have begun to be identified, drugs to target these pathways can now be developed.
AgeX is applying technology relating to cell immortality and regenerative biology, to aging and age-related diseases.
The company has three initial areas of product development: pluripotent stem cell-derived brown adipocytes; vascular progenitors; and induced tissue regeneration. Initial planned indications for these products are Type II diabetes, cardiac ischemia, and cancer respectively.
When a cell reaches the end of its life or becomes damaged beyond repair, it is supposed to either kill itself or signal the immune system to remove it.
Unfortunately, every so often this mechanism fails, the cell stays around indefinitely and starts poisoning its environment. Over time we accumulate more and more of these harmful, death-resistant senescent cells.
A recent study in rodents has shown that clearing senescent cells can both reduce the adverse effects of age-related diseases and extend the healthy lifespan by up to 35%.
Oisin is developing a cellular repair therapy based on a genetically-targeted intervention to clear senescent cells from our body.
Age-related macular degeneration (AMD) is the leading cause of vision loss among people over the age of 50.
AMD is thought to be caused by aggregation of A2E a toxic, non-degradable cellular waste product in our eye’s retinal cells.
Lysoclear is a molecular repair therapy based on the targeted delivery of exogenous A2E degrading enzymes to our retina cells to eliminate A2E, treat AMD and restore vision.
The team recently announced a Series-A offering to bring its product through Phase I clinical trials. LysoClear would be the first clinical candidate based on the repair and rejuvenation paradigm, pioneered by the SENS research foundation.